An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study.
Carlo LazzaroCarlo BaroneFrancesco CaprioniStefano CascinuAlfredo FalconeEvaristo MaielloMichele MilellaCarmine PintoMichele ReniGiampaolo TortoraPublished in: Expert review of pharmacoeconomics & outcomes research (2018)
Nab-P + G in MPC patients can be considered cost-effective for the INHS.